S2Medical (S2M) Q4 2024 earnings summary

Executive summary

• 2024 marked a turnaround with more than doubled net sales to 14.9 MSEK (7.0 MSEK prior year), mainly from the Abena partnership, and a swing to positive operating income of 5.8 MSEK from -15.3 MSEK.

• Cost optimization and strategic restructuring led to improved cash flow and a stronger foundation for long-term growth.

• Expansion into cosmetics via Eyracure acquisition and new patents in the US and South Africa broadened revenue streams.

Financial highlights

• Net sales for H2: 7.7 MSEK (3.6 MSEK); full year: 14.9 MSEK (7.0 MSEK), driven by Abena collaboration.

• Operating income for H2: -2.4 MSEK (-5.8 MSEK); full year: 5.8 MSEK (-15.3 MSEK).

• Net income for H2: -2.4 MSEK (-9.9 MSEK); full year: 5.8 MSEK (-22.7 MSEK).

• EPS for H2: -0.00 SEK (-0.04 SEK); full year: 0.01 SEK (-0.08 SEK).

• Cash flow for 2024: -0.5 MSEK (-2.2 MSEK prior year); liquidity at year-end: 1.0 MSEK.

Outlook and guidance

• Focus remains on accelerated commercialization, technological leadership, and continued cost optimization to achieve sustainable profitability.

• Expansion in cosmetics and functional skin health expected to create new long-term revenue opportunities.